CLOSE MENUThe priorities build on Sens. Shaheen and Collins previous work by encouraging manufacturers to reduce list prices while extending patient protections. The new priorities aim to increase competition and access to insulin products. The proposal specifically bans rebates on insulin products that are priced at 2006 levels, limits coinsurance to $35 for insured patients, and prohibits insurers from denying coverage of insulin. Sens. Shaheen and Collins have requested input from their colleagues and all stakeholders on their proposal before they introduce the final legislation. To read the full press release, click here.
Ameet Sarpatwari and colleagues from Harvard Medical School opined on the manufacturer restrictions of the 340B program in a JAMA Viewpoint article. The researchers outline the program’s history and past changes that have made the program into what it is today before discussing the possible implications of the manufacturers’ restrictions. They conclude by recommending Congress (1) allow contract pharmacies to participate in 340B and (2) empower HRSA with rulemaking abilities to prevent drug diversion and duplicate discounts. To read the full article, click here.
